ArticleInternational journal of molecular sciences2025
Prognostic Significance of Peripheral Blood Parameters as Predictor of Neoadjuvant Chemotherapy Response in Breast Cancer.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic value of prognostic nutritional index in breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Prognostic value of platelet to lymphocyte ratio (PLR) in breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Special Issue "Molecular Research and Cellular Biology of Breast Cancer".International journal of molecular sciences · 2026Article
- Development and validation of a biopsy-based model using tumor-associated neutrophils to predict neoadjuvant chemotherapy response in osteosarcoma: a large single-center retrospective cohort study.Journal of bone oncology · 2026Article
- ASO Author Reflections: Toward Personalized Neoadjuvant Therapy in HER2-Positive Breast Cancer-A Clinically Actionable Predictive Model.Annals of surgical oncology · 2026Article
- Analysis of Neutrophil/Lymphocyte Ratio as a Potential Biomarker Stratified by Breast Cancer Histologic Subtype.Diagnostics (Basel, Switzerland) · 2026Article
- Establishment and evaluation of novel prognostic biomarkers based on systemic coagulation-inflammation index and related genes in breast cancer.Frontiers in immunology · 2026Article
- Diagnostic value of peripheral blood inflammatory indices for breast cancer grade and immunohistochemical markers: a retrospective observational study.BMC cancer · 2025Observational
- Uncovering prognostic biomarkers through a pharmacovigilance study: the case of RDW.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- From Blood to Outcome: Inflammatory Biomarkers in Rectal Cancer Surgery at a Romanian Tertiary Hospital.Diseases (Basel, Switzerland) · 2025Article
- Association of the inflammatory microenvironment of obesity with pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy.Frontiers in endocrinology · 2025Article
- Systemic inflammatory indices and age-dependent severity in acute appendicitis: a retrospective cohort study.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The standard treatment for breast cancer typically includes surgery, often followed by systemic therapy and individualized treatment regimens. However, there is growing interest in identifying pre-therapeutic biomarkers that can predict tumor response to neoadjuvant chemotherapy (NACT). This study systematically evaluated various analytical parameters, including age, TNM stage, histological type, molecular subtype, and several biomarker ratios, such as the platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammatory index (SII), and prognostic nutritional index (PNI). We aimed to assess the predictive value of these parameters regarding the tumor's response rate to NACT. The analysis revealed a statistically significant association between the pathological complete response-pCR (absence of any detectable cancer cells in the tissue following neoadjuvant chemotherapy (NACT))-rate and NLR in the subgroup with values between 1 and 3 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.